retatrutide weight loss trials results π¨ Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and type 2 diabetes. π Mean body change at 80 weeks: β¬οΈ Eli Lilly infiltrates anti-obesity market
Pay in 4 interest-free payments of $7.30 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 1 - Aug 6






















